Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses.

Autor:	Baba MS; Endocrinology, Government Superspeciality Hospital, Srinagar, IND., Islam Mir SU; Endocrinology, Hamdard Institute of Medical Sciences and Research, New Delhi, IND., Bhat MH; Endocrinology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, IND., Laway BA; Endocrinology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, IND., Misgar RA; Endocrinology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Aug 03; Vol. 15 (8), pp. e42911. Date of Electronic Publication: 2023 Aug 03 (Print Publication: 2023).
DOI:	10.7759/cureus.42911
Abstrakt:	Background and objective Individuals with prolactinoma exhibit elevated rates of obesity, metabolic syndrome (MS), and dyslipidemia compared to their healthy counterparts. However, there is a lack of data regarding metabolic variance between male and female prolactinoma patients. Consequently, this study aimed to investigate and compare sex-specific discrepancies in metabolic abnormalities among individuals diagnosed with prolactinoma. Methods In this prospective study, 80 treatment-naïve patients with prolactinoma (12 males and 68 females) underwent clinical assessments and laboratory investigations. The measured parameters included blood glucose, total cholesterol (TC), triglycerides (TG), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), urea, creatinine, uric acid, and blood glucose levels. The patients were treated with cabergoline, a dopamine agonist, and reevaluated after 12 weeks. Results Forty-eight patients had microprolactinomas (all females), and 32 had macroprolactinomas (20 females, 12 males). The mean age was 28.30±7.49 years for females and 28.91±7.12 years for males (p=0.71). The median symptom duration was 12 months (range 1-72 months, IQR 4-16 months), with no significant difference between males (median 12 months, IQR 5-54 months) and females (median 12 months, IQR 10-24 months, p=0.620). The median serum prolactin (PRL) was 988 ng/mL (IQR 471-1,439) in males and 165 ng/mL (IQR 90-425) in females (p<0.05). Males showed higher HbA1c, BGF, TC, TG, LDL-C, and higher rates of obesity, MS, and diabetes mellitus. Treatment with cabergoline resulted in significant improvements in the HbA1c, BGF, TC, TG, and LDL-C levels. Conclusion Males with prolactinomas had larger tumor sizes and higher serum PRL levels than females. Additionally, males exhibited worse metabolic parameters than females. However, there was no significant difference in the duration of symptoms or age at diagnosis between the two groups. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Baba et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu